Macrophages

Human liver
#Liver disease #Macrophages #Phase I trial #Regenerative Medicine #Resolution Therapeutics

Resolution to present positive interim data for regenerative macrophage therapy

Resolution Therapeutics has revealed positive interim six-month data from its Phase I/II EMERALD trial evaluating RTX001, an investigational autologous engineered regenerative macrophage therapy (RMT), in patients with end-stage liver disease (ESLD).  The data showed a signal of efficacy on clinical outcomes of death, liver transplant and hepatic… Read More

#News

Macrophage
#Liver disease #Macrophages #Phase I trial #Resolution Therapeutics

Macrophage therapy trial in liver disease completes enrolment

The final patient has been treated in EMERALD, Resolution Therapeutics’ Phase I/II clinical trial evaluating its engineered Regenerative Macrophage Therapy (RMT), RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis.  Liver transplantation remains the only disease-modifying treatment option for patients with… Read More

#News

Fibrous dysplasia disease
#Fibrotic disease #Inflammatory diseases #Macrophages #Resolution Therapeutics

Resolution extends pipeline with in vivo RMT 

Resolution Therapeutics has extended its inflammatory and fibrotic disease pipeline with its in vivo regenerative macrophage therapy (RMT).  The announcement comes with Resolution executing Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering… Read More

#News

Cell and gene therapies
#Cell and gene therapy #Macrophages #Solid tumours #T-Cells

Laverock reports positive data from oncology programmes 

Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.  Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More

#Cancer Research #News

#Assays #Drug discovery #Imaging #Live cell analysis #Macrophages #Phenotyping #Technical Note

Optimise macrophage assays and boost immunology research

A new free resource from Lonza is now available entitled ‘Optimising macrophage polarisation and phagocytosis assays‘. Download this Technical Note to learn: Streamlined Macrophage Workflow: Transform cryopreserved or PBMC-derived monocytes into M1 or M2 macrophages using a reproducible, high-throughput protocol. Comprehensive Validation: Confirm phenotype and function with live-cell imaging… Read More

#News

#Assays #Drug discovery #Imaging #Live cell analysis #Macrophages #Phenotyping

Optimising macrophage polarisation and phagocytosis assays

Download this Technical Note to learn: Streamlined Macrophage Workflow: Transform cryopreserved or PBMC-derived monocytes into M1 or M2 macrophages using a reproducible, high-throughput protocol. Comprehensive Validation: Confirm phenotype and function with live-cell imaging and phagocytosis assays for application-ready results. Accelerated Research: Enhance drug discovery, immunotoxicology, and screening workflows with both… Read More

#Resources

#Drug discovery #Guide #iPSC #Macrophages #Pluripotent stem cells

Guide: Optimising macrophage differentiation from iPSCs

Facing challenges with macrophage differentiation from iPSCs? Discover valuable insights in this new Guide from Lonza: ‘Optimising Macrophage Differentiation from iPSCs with X-VIVO® Media.’ Get the guidance you need to overcome these obstacles to address challenges regularly faced by scientists, from drug discovery to QA/QC. Download the Guide for free… Read More

#News

#Drug discovery #iPSC #Macrophages #Pluripotent stem cells

Optimising macrophage differentiation from iPSCs with Lonza’s X-VIVO Media

Facing challenges with macrophage differentiation from iPSCs? Discover valuable insights in our mini review ‘Optimising Macrophage Differentiation from iPSCs with X-VIVO® Media.’ Get the guidance you need to overcome these obstacles to address challenges regularly faced by scientists, from drug discovery to QA/QC. Read More

#Resources

Liver cancer
#Macrophages #Oncology #Phase I trial #Pheast Therapeutics #Solid tumours

First patient receives anti-CD24 macrophage checkpoint inhibitor

Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours.  The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours.  The study’s primary objectives… Read More

#Cancer Research #News #Trending News

MHRA
#Cell therapy #Clinical trials #Liver disease #Macrophages #MHRA #Resolution Therapeutics

Green light for engineered macrophage cell therapy study 

Resolution Therapeutics has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I/II EMERALD study for its lead candidate RTX001 for patients with decompensated liver cirrhosis.   EMERALD is an open-label, Phase I/II study which will investigate the safety and… Read More

#News

#Cancer research #Macomics #Macrophages #Omics #Oncology #Tumour microenvironment (TME) #Turning Science into Business

Turning science into business: Exploiting macrophage biology

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role do they… Read More

#Cancer Research #Exclusive Content

Natural killer cells
#Cancer research #Icahn School of Medicine #Lung cancer #Macrophages #Oncology #Preclinical investigations

Macrophages suppress natural killer cells in lung cancer tumours

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells. “Our… Read More

#Cancer Research #News

Macrophage
#AACR 2023 #Cancer research #Macomics #Macrophages #Oncology #Tumour microenvironment (TME)

Benefits of reprogramming tumour macrophages presented at AACR

UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players… Read More

#Cancer Research #News

Macrophages
#Antibodies #Cancer research #Collaboration #Immuno-oncology #Japan #Macrophages #Oncology #Partnership #UK

Drug discovery partners from UK and Japan target macrophages

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More

#Cancer Research #News

#CRISPR #CRISPR screening #Drug targets #Drug validation #Macrophages

Understanding macrophages for future therapy success: event

Macrophages are involved in many different disease states, so understanding more about how these cells are regulated is important for future therapies for a range of diseases.  CD14, a co-receptor for bacterial lipopolysaccharide, and can potentiate inflammatory signalling when upregulated on myeloid cells during differentiation. Join DDW for this webinar,… Read More

#Editor's Choice #News